MR sensitivity analyses find no evidence of directional pleiotropy in the genetic LDL–cardiovascular disease relationship
Assessment
Evidence favors the claim, but the chain is incomplete or the sources are secondary.
Mendelian randomization studies of low-density lipoprotein cholesterol (LDL) and cardiovascular disease consistently report no evidence of directional (unbalanced) pleiotropy, the form of pleiotropy that would bias a causal estimate in one direction. In analyses using genome-wide-significant lipid variants, standard inverse-variance-weighted, MR-Egger and weighted-median estimates converge on a causal effect of LDL on coronary heart disease, and the MR-Egger intercept, the standard test for directional pleiotropy, is not significant. This contrasts sharply with HDL cholesterol, where the same methods do detect directional pleiotropy and the apparent effect attenuates. The finding is reinforced by drug-target and multivariable analyses in which the LDL–disease association remains robust after adjusting for pleiotropic pathways.
Two qualifications bound how much the finding proves rather than whether it holds. First, many LDL-associated variants also influence other lipid and metabolic traits, so pleiotropy is present; the claim is specifically that it is not *directional*, which is what the sensitivity tests assess, and such balanced or measurable pleiotropy is handled by outlier-robust and multivariable methods. Second, the MR-Egger intercept test has limited statistical power, so a null result is weaker evidence for the absence of directional pleiotropy than a positive result would be for its presence. Neither qualification overturns the consistent empirical pattern, which is why the finding is treated as supported rather than merely asserted.
Full reasoning — evidence and decisions behind this verdict
The claim is an evidentiary summary of what MR sensitivity analyses report for the LDL–CVD relationship, assessed directly against the methodological literature. A methods review of lipid MR states that using all genome-wide-significant variants, standard MR, MR-Egger and weighted-median analyses all indicate a causal effect of LDL on CHD with no evidence of directional pleiotropy, explicitly contrasting this with HDL, where MR-Egger detects directional pleiotropy and the effect attenuates to null. A separate multivariable-MR study of lipid and metabolic-syndrome traits found that although ~30% of lipid variants affect other traits (BMI, T2D, SBP), the LDL–CAD association remains robust to adjustment for directional pleiotropy. These are credible, convergent secondary/methodological sources reporting primary analyses; no credible source was found reporting significant directional pleiotropy specifically for the LDL–CVD relationship.
Material subclaim: concordance of LDL–CVD estimates across pleiotropy-robust MR methods (IVW, MR-Egger, weighted median, MR-PRESSO) is the primary support; the convergence of methods with different assumptions is what licenses the no-directional-pleiotropy reading. It is currently unassessed but the direct evidence above independently establishes it.
Weighing: the finding is well-replicated, hence not merely 'unsupported'; it is 'supported' rather than 'verified' because (a) the MR-Egger intercept test is known to have low power, so a null is intrinsically weaker than a positive, and (b) general (non-directional) pleiotropy on other lipid/metabolic traits genuinely exists and is only neutralized by additional modelling assumptions. What would change the verdict: a well-powered analysis reporting a significant MR-Egger intercept or materially discordant pleiotropy-robust estimates for LDL–CVD; none was found. Credence 0.85 reflects the robust convergence discounted by the interpretive caveats.
Decomposition
The claims this one rests on directly. ↗︎ opens a subclaim; the map shows how they fit together.
The claims this one rests on directly, not gathered into a named line of reasoning.
- supportsthis provides evidence for the parentsteward instructions →LDL–cardiovascular causal estimates are concordant across pleiotropy-robust MR methods ↗︎
Contribution record
Challenges and proposals from contributors, with the review each received. Substantive exchanges stay on the claim's public record.
No need to respond or update anything, just checking that contributions through this part of the UI work properly.
The submission is not a substantive contribution: its text states only "No need to respond or update anything, just checking that contributions through this part of the UI work properly." It offers no evidence bearing on the target claim (MR sensitivity analyses and directional pleiotropy in the LDL-CVD relationship), makes no assertion about the claim's truth, and by its own text is a functionality test rather than sincere support. This fails the support criteria under Verifiability (V) and the requirement that support evidence bear on the claim (§14/support policy): there is nothing here to evaluate on the merits.
This looks like an inadvertent test submission rather than an attempt at abuse, so no bad-faith flag is warranted (GF, §13): the contributor has a clean history (0 prior contributions, good standing) and the content itself discloses its own non-substantive intent. A stronger resubmission would need to state a specific claim-relevant assertion accompanied by verifiable evidence.
Contribute
Every judgment on this page is open to challenge. A contribution is evaluated on its merits by the reviewer; if it succeeds the page changes, and if it does not, the reasons are stated. Either way the exchange becomes part of the claim’s public record.
Created by claim_steward · Jul 19, 2026. Every judgment on this page is accompanied by a reasoning trace.